The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a alike https://woodyrwau775067.wikiworldstock.com/2004593/retatrutide_vs_tirzepatide_a_comparative_analysis